Results 291 to 300 of about 1,940,460 (362)

Urothelial carcinoma: Perioperative considerations from top to bottom

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Urothelial carcinoma is an aggressive entity that is associated with significant morbidity, but there have been major advances in both our understanding of and treatment options for patients with this disease. In this review, the authors focus on novel therapeutic and diagnostic approaches in the perioperative setting, with an emphasis on ...
Wesley Yip, Salvador Jaime‐Casas, Anjaney Kothari, Mary Sullivan, Leslie K. Ballas, Domenique Escobar, Anne K. Schuckman, Jonathan E. Rosenberg, Jonathan A. Coleman   +8 more
wiley   +1 more source

The function of T cells in immune thrombocytopenia. [PDF]

Front Immunol
Bu S, Liu M, Yang L, Lee P, Miller H, Park CS, Byazrova M, Filatov A, Benlagha K, Gaber T, Buttgereit F, Gong Q, Zhai Z, Liu C.   +13 more
europepmc   +1 more source

Immune Thrombocytopenia Triggered by Sildenafil-Containing Rhino 69 Platinum 1000: A Case Report. [PDF]

Cureus
Saripalli A, Sharma R, Dao KT, Fox K.
europepmc   +1 more source

Immune Thrombocytopenia in Pregnancy

International Journal of Contemporary Medical Research [IJCMR], 2018
openaire   +1 more source

The Evolution and Recent Advances in Diagnostic Criteria for Idiopathic Multicentric Castleman Disease

American Journal of Hematology, Volume 100, Issue 11, Page 2064-2073, November 2025.
Idiopathic Multicentric Castleman Disease. ABSTRACT Idiopathic multicentric Castleman disease (iMCD) is a rare cytokine‐driven disorder characterized by systemic inflammation, organ dysfunction, and altered lymph node microscopic architecture. Over the past decade, diagnostic criteria have evolved significantly, integrating clinical, histopathological,
FNU Alnoor, Nicholas C. Spies, Jyoti Kumar, Peyman Samghabadi, Oscar Silva, Matt X. Luo, Karen M. Chisholm, Jingjing Zhang, Alexandra Rangel, David Ng, Peng Li, Robert S. Ohgami   +11 more
wiley   +1 more source

Narsoplimab Results in Excellent Survival in Adults and Children With Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy (TA‐TMA)

American Journal of Hematology, Volume 100, Issue 11, Page 2040-2051, November 2025.
ABSTRACT Inappropriate complement activation is a key driver of hematopoietic cell transplant‐associated thrombotic microangiopathy (TA‐TMA). Treatment with narsoplimab, an inhibitor of MASP‐2, the effector enzyme of the lectin pathway, resulted in a response rate of 61% in a Phase 2 clinical trial in adults with TA‐TMA.
Michelle L. Schoettler, Sunil Kumar Pusarla, Narinder Nangia, Miguel‐Angel Perales, Rafael F. Duarte, Andreas Grauer, Alessandro Rambaldi   +6 more
wiley   +1 more source